| Literature DB >> 29312538 |
Qi-Lin Zhang1,2, Zheng-Qing Xie1,2, Ming-Zhong Liang3, Bang Luo4, Xiu-Qiang Wang1, Jun-Yuan Chen1.
Abstract
The gene expression associated with immune response to bacteria/bacterial mimic has been extensively analyzed in amphioxus, but remains largely unknown about how gene are involved in the immune response to viral invasion at expression level. Here, we analyze the rRNA-depleted transcriptomes of Branchiostoma belcheri using strand-specific RNA-seq in response to the viral mimic, poly (I:C) (pIC). A total of 5,317 differentially expressed genes were detected at treatment group by comparing with control. The gene with the most significant expression changes (top 15) after pIC challenge and 7 immune-related categories involving 58 differently expressed genes were scrutinized. By functional enrichment analysis of differently expressed genes, gene ontology terms involving response to stress and stimulus, apoptosis, catabolic and metabolic processes and enzyme activity were overrepresented, and several pathways related to immune signaling, immune response, cancer, apoptosis, viral disease, metabolism were activated after pIC injection. A positive correlation between the qRT-PCR and strand-specific RNA-seq data confirmed the accuracy of the RNA-seq results. Additionally, the expression of genes encoding NLRC5, CASP1, CASP6, CYP450, CAT, and MDA5 were induced in B. belcheri under pIC challenge. Our experiments provide insight into the immune response of amphioxus to pIC and valuable gene expression information for studying the evolution of antiviral immunity in vertebrates.Entities:
Keywords: Branchiostoma belcheri; Immunology; antiviral immunity; poly (I:C); strand-specific RNA-seq; transcriptome analysis
Year: 2017 PMID: 29312538 PMCID: PMC5752451 DOI: 10.18632/oncotarget.21553
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Top 15 most up- and down-regulated genes between control and treatment groups.
| GeneID | log2Ratio(treatment/control) | Description | Gene name | FDR |
|---|---|---|---|---|
| 001470R | 13.78 | Leukocyte cell-derived chemotaxin 1 | LECT1 | 0 |
| 161330F | 12.38 | Hypothetical protein | / | 7.99E-06 |
| 141980F | 12.05 | EGF-like domain-containing protein 1 | SCUBE1 | 7.73E-244 |
| 024370R | 11.86 | Histone H1 | H1 | 1.73E-220 |
| 250030R | 11.40 | Lecithin retinol acyltransferase | LRAT | 3.59E-175 |
| 141990F | 10.64 | C-type lectin 6 | CTL6 | 1.03E-116 |
| 101420F | 10.53 | RNA-directed DNA polymerase from mobile element jockey | POL | 2.79E-110 |
| 277890F | 10.53 | Hypothetical protein | / | 3.65E-110 |
| 084230F | 10.45 | Synapse differentiation-inducing gene protein 1-like | SYNDIG11 | 3.29E-105 |
| 024270F | 10.36 | Histone H2B | H2B | 1.49E-100 |
| 024300F | 10.34 | Histone H2A | H2A | 1.42E-99 |
| 276140F | 10.01 | Receptor-transporting protein 3 | RTP3 | 2.74E-83 |
| 209870F | 10.00 | Mucin-like protein 1 | MUCL1 | 4.98E-83 |
| 261040F | 9.60 | FAS-associated death domain protein | FADD | 6.14E-67 |
| 094460R | 9.36 | Natural killer cells antigen CD94 | KLRD1 | 8.78E-59 |
| 146060R | -13.19 | Chondroitin proteoglycan 2 | CPG2 | 8.81E-123 |
| 112420F | -12.65 | Tumor necrosis factor receptor superfamily member 16 | TNFRSF16 | 0.000131 |
| 074740F | -12.47 | Type I inositol 3,4-bisphosphate 4-phosphatase | INPP4A | 1.60E-11 |
| 096490F | -12.42 | Hypothetical protein | / | 1.43E-303 |
| 180950F | -12.09 | Latent-transforming growth factor beta-binding protein 1 | LTBP1 | 3.19E-257 |
| 050170F | -11.88 | Adhesion G protein-coupled receptor | AGPCR | 3.90E-231 |
| 073740R | -10.76 | Uromodulin | UMOD | 1.11E-128 |
| 157820R | -10.75 | Guanylate-binding protein 5 | GBP5 | 1.27E-27 |
| 073640F | -10.71 | Protein eva-1 homolog C | EVA1C | 2.20E-125 |
| 093180R | -10.53 | Delta-like protein 4 | DLL4 | 4.37E-227 |
| 050100R | -10.38 | Complement component C7 | C7 | 6.05E-210 |
| 254530F | -10.07 | E3 ubiquitin-protein ligase MIB1 | MIB1 | 0 |
| 009460R | -9.89 | Hypothetical protein | / | 7.56E-81 |
| 115020F | -9.66 | Epidermal growth factor-like protein 7 | EGFL7 | 1.18E-71 |
| 115020F | -9.66 | Interferon-induced protein 44 | IFI44 | 1.18E-71 |
DEGs typically involved in immune responses.
| Category and gene name | log2Ratio | Diff | FDR | Gene name |
|---|---|---|---|---|
| Heat shock 70 kDa protein | 4.64 | UP | 0.000346 | HSP70 |
| Heat shock factor protein 5 | 3.11 | UP | 8.48E-06 | HSF5 |
| Small heat shock protein 25 | 2.24 | UP | 2.43E-31 | HSP25 |
| Activator of 90 kDa heat shock protein ATPase homolog 2 | -1.21 | DOWN | 1.63E-11 | AHSA2 |
| Heat shock protein 83 | -1.73 | DOWN | 0 | HSP83 |
| Heat shock protein HSP 90 | -2.27 | DOWN | 0 | HSP90 |
| Heat shock 22 kDa protein | -2.93 | DOWN | 2.38E-85 | HSP22 |
| Coagulation factor V | 6.18 | UP | 1.02E-09 | F5 |
| Fibrinogen gamma chain | 4.25 | UP | 1.96E-13 | FGG |
| Coagulation factor VII | 2.15 | UP | 7.02E-07 | F7 |
| Alpha-tectorin-like | 2.12 | UP | 4.79E-09 | TECTA |
| Urokinase-type plasminogen activator | 1.35 | UP | 6.42E-14 | PLAU |
| Coagulation factor XII | 1.16 | UP | 2.69E-07 | F12 |
| Haptoglobin-like | -1.56 | DOWN | 1.99E-05 | HP |
| Coagulation factor IX | -1.84 | DOWN | 3.38E-06 | F9 |
| Complement component C1q-like | -2.87 | DOWN | 1.17E-09 | C1qL |
| Complement component C8 beta | -8.90 | DOWN | 0 | C8B |
| Complement component C7 | -10.38 | DOWN | 6.05E-210 | C7 |
| C-type lectin 6 | 10.64 | UP | 1.03E-116 | CTL6 |
| Protein NLRC5 | 5.96 | UP | 1.44E-08 | NLRC5 |
| Toll-like receptor 1 | 5.05 | UP | 3.38E-05 | TLR1 |
| NACHT, LRR and PYD domains-containing protein 9 | 2.25 | UP | 6.95E-75 | NLRP9 |
| NACHT, LRR and PYD domains-containing protein 4 | 2.01 | UP | 1.46E-19 | NLRP4 |
| NACHT, LRR and PYD domains-containing protein 3 | 1.66 | UP | 7.00E-21 | NLRP3 |
| Soluble scavenger receptor cysteine-rich domain-containing protein | -1.02 | DOWN | 1.10E-53 | SRCR5D |
| C-type lectin 9a | -1.50 | DOWN | 8.06E-07 | CTL9A |
| Peptidoglycan-recognition protein (PGRP) SD | -2.06 | DOWN | 1.44E-45 | PGRP-SD |
| Peptidoglycan-recognition protein (PGRP) SC2 | -2.09 | DOWN | 4.15E-54 | PGRP-SC2 |
| Melanoma differentiation associated genec5 | -2.22 | DOWN | 7.07E-19 | MDA5 |
| Intelectin-1 | -2.60 | DOWN | 4.75E-19 | ITLN1 |
| Scavenger receptor cysteine-rich domain-containing protein | -3.27 | DOWN | 1.90E-22 | SRCR4D |
| Cadherin-like protein 23-like | 2.22 | UP | 2.86E-25 | CDH23L |
| Integrin beta-4 | -1.04 | DOWN | 3.77E-79 | ITGB4 |
| Claudin-11 | -2.26 | DOWN | 1.02E-19 | CLDN11 |
| Interleukin-17D | 2.69 | UP | 1.35E-13 | IL17D |
| Tumor necrosis factor alpha | 1.82 | UP | 4.90E-16 | TNFα |
| Interferon regulatory factor 6 | 1.35 | UP | 7.11E-31 | IRF6 |
| Interleukin 17 receptor D | 1.11 | UP | 0.000949 | IL17DR |
| Inhibin beta E chain | -2.38 | DOWN | 6.26E-55 | INHBE |
| Interferon-induced protein 44 | -9.66 | DOWN | 1.18E-71 | IFI44 |
| FAS-associated death domain protein | 9.60 | UP | 6.14E-67 | FADD |
| Apoptosis inhibitor IAP | 2.65 | UP | 1.05E-201 | IAP |
| cAMP-dependent protein kinase | 2.07 | UP | 2.37E-15 | PKA |
| Caspase activity and apoptosis inhibitor 1 | 1.32 | UP | 1.31E-08 | CAAP1 |
| Apoptosis-inducing factor 2 | -3.23 | DOWN | 1.14E-58 | AIFM2 |
| Apoptotic initiator caspases (Caspase-2) | 9.20 | UP | 9.60E-54 | CASP2 |
| Tumor necrosis factor receptor superfamily member 6B | 8.55 | UP | 1.82E-37 | TNFRSF6 |
| Caspase-1 | 6.24 | UP | 1.18E-18 | CASP1 |
| Apoptotic initiator caspases (Caspase-8) | 4.75 | UP | 0.000192 | CASP8 |
| TNF receptor-associated factor 2 | 4.19 | UP | 1.45E-66 | TRAF2 |
| Apoptotic effetor caspases (Caspase-3) | 1.70 | UP | 1.59E-07 | CASP3 |
| Apoptotic effetor caspases (Caspase-7) | 1.51 | UP | 1.99E-18 | CASP7 |
| TNF receptor-associated factor 3 | 1.19 | UP | 1.80E-44 | TRAF3 |
| TNF receptor-associated factor 1 | -1.02 | DOWN | 2.69E-07 | TRAF1 |
| TNF receptor-associated factor 6 | -2.62 | DOWN | 2.12E-162 | TRAF6 |
| Myeloid differentiation primary response protein MyD88 | -3.36 | DOWN | 3.40E-07 | MyD88 |
| Apoptotic effetor caspases (Caspase-6) | -6.62 | DOWN | 2.37E-24 | CASP6 |
| Tumor necrosis factor receptor superfamily member 16 | -12.65 | DOWN | 0.000131 | TNFRSF16 |
Results of pathway enrichment analysis of DEGs, sorted by significance levels.
| Pathway ID | Pathway | FDR |
|---|---|---|
| ko05416 | Viral myocarditis | 5.09E-06 |
| ko05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 7.53E-06 |
| ko04621 | #NOD-like receptor signaling pathway | 2.11E-05 |
| ko05215 | Prostate cancer | 4.74E-05 |
| ko05200 | Pathways in cancer | 1.08E-04 |
| ko04060 | #Cytokine-cytokine receptor interaction | 1.14E-04 |
| ko05410 | Hypertrophic cardiomyopathy (HCM) | 5.27E-04 |
| ko05133 | Pertussis | 5.30E-04 |
| ko00590 | Arachidonic acid metabolism | 7.10E-04 |
| ko01100 | Metabolic pathways | 8.12E-04 |
| ko05218 | Melanoma | 8.92E-04 |
| ko05320 | Autoimmune thyroid disease | 8.92E-04 |
| ko04370 | VEGF signaling pathway | 2.95E-03 |
| ko05322 | Systemic lupus erythematosus | 2.95E-03 |
| ko05414 | Dilated cardiomyopathy | 3.01E-03 |
| ko00071 | Fatty acid metabolism | 3.01E-03 |
| ko04010 | #MAPK signaling pathway | 3.19E-03 |
| ko00592 | alpha-Linolenic acid metabolism | 3.19E-03 |
| ko04210 | #Apoptosis | 4.06E-03 |
| ko04622 | #RIG-I-like receptor signaling pathway | 4.57E-03 |
| ko00350 | Tyrosine metabolism | 5.06E-03 |
| ko05134 | Legionellosis | 7.37E-03 |
| ko04064 | #NF-kappa B signaling pathway | 8.22E-03 |
| ko04620 | #Toll-like receptor signaling pathway | 9.16E-03 |
| ko04612 | #Antigen processing and presentation | 4.89E-02 |
#: Directly immune-related KEGG pathways
Figure 1Correlation between relative fold changes in expression based on ssRNA-seq and qRT-PCR analyses
15 differentially expressed genes (DEGs) identified by ssRNA-seq were assessed by qRT-PCR of the same samples. Each black dot indicates the relative expression fold change between the treatment and control groups according to ssRNA-seq (x-axis) and qRT-PCR (y-axis). IBM SPSS Statistics 22 was used for statistical analysis.
Figure 2Dynamic expression changes of six DEGs in B. belcheri injected with pIC and assessed at different time points
The results are presented as relative to the expression level of EF1A and are shown as the mean± SD. *P < 0.05 and **P < 0.01 vs. control. IBM SPSS Statistics 22 was used for statistical analysis, and significance was evaluated by one-way ANOVA test.